Immix Biopharma, Inc.
No enriched coverage for $IMMX in the last 7 days.
No SEC Form 4 filings for $IMMX in the last 30 days.
The article says convicted fugitive former doctor Ronald Fischer, 70, appeared in Rhode Island court under an alias, after being arrested in July 2024 while working as Chief Medical Officer for Immix Biopharma. It reports Immix filed an SEC Form 8-K stating “Richard Graydon” was terminated and is no longer with the company, and that shareholder law firms are investigating hiring practices.
According to Stat News and an SEC filing by California-based Immix Biopharma, Richard Graydon, an alias for fugitive Ronald Fischer, was arrested July 16 in New York after 20 years on the run. Immix said it terminated Graydon on Friday for reasons unrelated to company activities and expects no material business impact. Atossa previously hired him as interim CMO.
US Marshals said fugitive Richard Fischer used the alias Richard Graydon, which matches a doctor and biotech executive Immix Biopharma hired as chief medical officer in March. Immix told the SEC it terminated Graydon on Friday for reasons unrelated to company activities. Immix removed his bio and a hiring press release; STAT could not verify his resume.
Recent IMMX coverage spans financial news, corporate actions and market movers.
The 8-K disclosure ties Immix’s leadership hiring and board background-check process to alleged fraud, raising governance and litigation risk.
Immix faces immediate headline and compliance risk from the termination of a senior medical hire who was allegedly a long-running fugitive.
The key tradable development is Immix’s sudden termination of its CMO amid allegations he may be a wanted fugitive, raising governance and reputational risk.
Governance scandal tied to the CMO and pre-BLA trial readout timing likely increases execution and regulatory risk, pressuring valuation.
The report links a terminated CMO hire to a long-running fugitive case, creating reputational and governance risk and likely near-term multiple compression.
alphai scores every news story that mentions IMMX with an AI model for sentiment and relevance, and aggregates insider trades from Immix Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The article says convicted fugitive former doctor Ronald Fischer, 70, appeared in Rhode Island court under an alias, after being arrested in July 2024 while working as Chief Medical Officer for Immix Biopharma. It reports Immix filed an SEC Form 8-K stating “Richard Graydon” was terminated and is no longer with the company, and that shareholder law firms are investigating hiring practices.
6 min readAccording to Stat News and an SEC filing by California-based Immix Biopharma, Richard Graydon, an alias for fugitive Ronald Fischer, was arrested July 16 in New York after 20 years on the run. Immix said it terminated Graydon on Friday for reasons unrelated to company activities and expects no material business impact. Atossa previously hired him as interim CMO.
7 min readUS Marshals said fugitive Richard Fischer used the alias Richard Graydon, which matches a doctor and biotech executive Immix Biopharma hired as chief medical officer in March. Immix told the SEC it terminated Graydon on Friday for reasons unrelated to company activities. Immix removed his bio and a hiring press release; STAT could not verify his resume.
6 min readInvesting.com reports Immix Biopharma (IMMX) shares fell 11.6% in morning trading after STAT News said the company’s CMO hired in March 2026 under “Dr. Richard Graydon” was actually Ronald Fischer, a fugitive arrested in July 2026. Immix said in an 8-K that “Graydon” was terminated. The drop came ahead of NEXICART-2 trial topline data in Q3 2026.
6 min readImmix Biopharma Inc (NASDAQ:IMMX) shares fell about 13% after STAT News reported that a fugitive, Ronald Fischer, appeared to have worked for the company under the name Richard Graydon. Immix terminated Graydon via an 8-K, saying the firing is unrelated to his activities and expects no material business impact.
4 min readLifesci Capital began coverage of Immix Biopharma (NASDAQ:IMMX) with an “outperform” rating and a $19.00 price target, implying 102.19% upside from the prior close, according to Benzinga. Other analysts cited mixed views: Morgan Stanley “overweight” ($20), Mizuho “outperform” ($15), and Weiss “sell (d-)”. IMMX traded at $9.40 after reporting Q1 EPS of -$0.18 vs -$0.19 expected.
3 min readA financial analyst has increased the price target for Immix Biopharma (IMMX) by 25.64%. The new target is set at $16.66. This adjustment indicates a more optimistic outlook on the company's stock valuation from the analyst.
2 min readImmix Biopharma (NASDAQ: IMMX) reported quarterly earnings per share (EPS) of ($0.28), missing the consensus estimate of ($0.16) by ($0.12). Shares experienced a 6.5% decline to $8.15 following the announcement. Despite the earnings miss, analysts maintain a "Moderate Buy" consensus rating with an average target price of $18.00, and institutional investors have recently increased their holdings in the company.
4 min readImmix Biopharma's lead CAR-T candidate, NXC-201, shows promise in treating relapsed/refractory amyloid light chain amyloidosis (r/r ALA) based on positive clinical updates from the NEXICART-2 trial. The company anticipates a final readout in mid-2026 and plans to submit a biologics license application (BLA) to the FDA by the end of 2026, provided results remain supportive. Alongside these developments, a $100 million fund-raise is expected to finance operations until mid-2027, leading Edison Investment Research to increase Immix's valuation to $373.2 million, or $7.2 per share.
4 min read- Former Chimerix ( CMRX, acquired by Jazz for $935 million ) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic ...
3 min read
